Sales reps push new "me-too" drugs with free samples  [ not in citation given ] that are more expensive than existing generic drugs , such as Nexium which costs three times as much as its predecessor Prilosec, with no evidence of improved efficacy.   With beta-blockers and statins, me-too drugs have improved results, and increased competition while lowering prices.  As me-too drugs are similar but new, their side effects can be unknown and not well understood.  Pharmaceutical marketing / reps assert a me-too drug may work better than another, but they "don’t test their me-too drugs in people who have not done well with an earlier drug of the same class." 
These include testing drugs on unrepresentative, "freakishly ideal" patients; comparing new drugs to something known to be ineffective, or effective at a different dose or if used differently; conducting trials that are too short or too small; and stopping trials early or late.  It also includes measuring uninformative outcomes; packaging the data so that it is misleading; ignoring patients who drop out (. using per-protocol analysis , where only patients who complete the trial are counted in the final results, rather than intention-to-treat analysis , where everyone who starts the trial is counted); changing the main outcome of the trial once it has finished; producing subgroup analyses that show apparently positive outcomes for certain tightly defined groups (such as Chinese men between the ages of 56 and 71), thereby hiding an overall negative outcome; and conducting " seeding trials ," where the objective is to persuade physicians to use the drug. 
The proprietary PAT signal is a non-invasive measure of the arterial pulsatile volume changes at the fingertip. PAT signal is a surrogate of changes in the sympathetic nervous system that are associated with Sleep Disordered Breathing (SDB) events and specific “signatures” of sleep stages. The WatchPAT has an embedded advanced actigraphy that when coupled with PAT signal enables the separation between sleep and wake periods and thus provides accurate True Sleep Time.
PAT signal attenuation, and acceleration pulse rate- directly reflect immediate digital arteries vasoconstriction and increase heart rate. Both of which, are direct indicators of arousals and micro-arousals that are part of the SDB underlying mechanism and present in each such event.
When further enhanced with oxygen blood desaturations and resaturations measured with the embedded pulse oximeter sensor, the proprietary algorithm accurately calculates the SDB clinical parameters such as AHI, EDI and ODI that utilize True Sleep Time and Complete Sleep Architecture (Deep, Light and REM), providing the physician with a full comprehensive assessment of the patient.